145 related articles for article (PubMed ID: 9436031)
1. [Clinical application for gene therapy in prostate cancer].
Gotoh A; Kamidono S; Chung LW
Hinyokika Kiyo; 1997 Nov; 43(11):829-33. PubMed ID: 9436031
[TBL] [Abstract][Full Text] [Related]
2. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
3. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
8. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence.
Steiner MS; Zhang Y; Farooq F; Lerner J; Wang Y; Lu Y
Cancer Gene Ther; 2000 Mar; 7(3):360-72. PubMed ID: 10766342
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
[TBL] [Abstract][Full Text] [Related]
13. In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia.
Park HS; Cheon J; Cho HY; Ko YH; Bae JH; Moon DG; Kim JJ
Gene Ther; 2003 Jul; 10(13):1129-34. PubMed ID: 12808443
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
16. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde.
Steiner MS; Zhang X; Wang Y; Lu Y
Cancer Res; 2000 Aug; 60(16):4419-25. PubMed ID: 10969787
[TBL] [Abstract][Full Text] [Related]
18. Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells.
Peng W; Chen J; Huang YH; Sawicki JA
Gene Ther; 2005 Nov; 12(21):1573-80. PubMed ID: 16034457
[TBL] [Abstract][Full Text] [Related]
19. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
[TBL] [Abstract][Full Text] [Related]
20. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]